N2O anesthesia may exacerbate hyperhomocysteinemia and endothelial dysfunction in patients with renal impairment

To the Editor: Patients with renal impairment have elevated homocysteine levels and are at high risk of cardiovascular complications [1]. Herein, we caution against the use of nitrous oxide (N2O) anesthesia for these patients.

Under most conditions, N2O appears to be inert, but prolonged exposure to the gas leads to significant increases in plasma homocysteine levels in patients presenting for elective craniotomy [2]. N2O directly inhibits methionine synthase, which contains cobalamin as a prosthetic group and catalyzes a folate-dependent conversion of homocysteine to methionine. Recently, Selzer et al [3] have described the neurologic deterioration and death of a child anesthetized twice with N2O before the diagnosis of 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency was established. The N2O-induced defect of methionine synthase superimposed on an inherited defect of MTHFR caused the death of the reported patient. The adverse effects of N2O were reported in two other children with severe dietary cobalamin deficiency. One developed acute neurologic deficit six days after N2O anesthesia, and the other showed hypotonia, dehydration, and acidosis three weeks after N2O anesthesia.

Acute rise in plasma homocysteine level causes substantial impairment of endothelial function in healthy volunteers [4]. It is likely that when such endothelial dysfunction occurs in patients with renal impairment, it exacerbates the vascular dysfunction. The above-mentioned catastrophic events may provide us a cautionary message; plasma homocysteine and methionine levels should be closely monitored in patients with renal impairment undergoing N2O anesthesia. Pretreatment with vitamins (folic acid, vitamin B6, and B12) may block the N2O-induced increase in homocysteine level in at-risk individuals.

HIROKAZU TSUKAHARA, YUKIKO TOTOROKI, MASAIRO HIRAOKA, AND MITSUFUMI MAYUMI
Fukui, Japan

Failure to follow K/DOQI guidelines decreases effectiveness of access flow surveillance

To the Editor: The major drawback of the recent study on graft surveillance [1] is its failure to use major Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines.

The K/DOQI ΔQa guideline (25% flow drop over 4 months, or a drop >20% within 1 month in the 1999 version) was not applied. Flow trends are considered to be more predictive of thrombosis than a single flow measurement (Qa). The authors argue that the application of the ΔQa criterion would not have altered the study outcome based on their previous study [2]. First, their previous study did not use interventions. Second, the results of that study have been disputed because of an incorrect statistic approach and multiple errors in calculations [3, 4]. Furthermore, when this study was analyzed by others [3, 4], it was shown to actually support the K/DOQI guidelines. Failure to apply both K/DOQI thresholds resulted in decreased preemptive percutaneous transluminal angioplasty (PTA) rate to 0.34/patient-years versus 0.54/patient-years in a study in which both flow thresholds were used [5], suggesting the patient’s undertreatment.

Qa should be measured during the first 1 hour of hemodialysis (K/DOQI). The hemodynamic uncertainties related to patient status late in the treatment (15 minutes before the end, according to the authors’ protocol) could impact flow results significantly. This brings into question all access flow data.

The authors’ noncompliance with the K/DOQI guidelines decreased the quality of their clinical outcomes. Their article sends a misleading message to the hemodialysis community about the effectiveness of flow surveillance.

Correspondence to Hirokazu Tsukahara, M.D., Ph.D., Department of Pediatrics, Fukui Medical University, Fukui 910-1193, Japan.
E-mail: hituka@fnursa.fukui-med.ac.jp

MICHAEL LEVINE
Milwaukee, Wisconsin

REFERENCES

E-mail: htsuka@fnursa.fukui-med.ac.jp